Table 3.

Summary of Ongoing Trials of Neurological Manifestations in COVID-19 Patients.

Study ID	Study Title	Study Type	Study Status	Country	Study Objective/Aim
1	Testing for dysautonomia in patients hospitalized for SARS-CoV-2 infection (COVID-19): COVIDANS study	Prospective cohort study	Recruiting	France, single center	To record the long-term variability in heart rate, reflecting autonomic balance, of patients screened positive for SARS-CoV-2
2	COVID-19 prevalence and cognitive deficits in neurological patients	Prospective cohort study	Not yet recruiting	Denmark, multicenter	To investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
3	Cohort of patients with COVID-19 presenting neurological or psychiatric disorders (CoCo-neurosciences)	Retrospective cohort study	Not yet recruiting	France, single center	Impact of neurological or psychiatric manifestations in patients with COVID-19 infection
4	Neurologic manifestations of COVID-19 in children	Prospective cohort study	Recruiting	United States, multicenter	Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19
5	Frequency and clinical evolution of olfactory and taste disorders in COVID-19 patients	Retrospective study	Enrolling by invitation	France, single center	To evaluate prevalence of anosmia and dysgeusia in COVID-19 diagnosed patients
6	Neurodegeneration markers and neurological course in severe Covid-19 infection	Prospective, single group study	Not yet recruiting	France, single center	Examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection using neurodegeneration markers level
7	Qualitative and quantitative evaluation of anosmia over time in clinically symptomatic patients tested for COVID-19 infection	Prospective cohort study	Recruiting	France, single center	To describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection
8	Acute encephalopathy in critically ill patients with COVID-19	Prospective cohort study	Recruiting	United States, France, multicenter	Reporting the prevalence of acute encephalopathy at initial management in Intensive care or neurocritical care
9	Finding out if COVID-19 Infection can be predicted by changes in smell and/or taste	Prospective cohort study	Recruiting	United Kingdom, single center	To compare case fatality rate in COVID-19 positive with documented history of loss/reduced sense of smell and/or taste compared to COVID-19 positive with documented history of no loss/reduced sense of smell and/or taste
10	Trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity	RCT	Not yet recruiting	France, single center	Given budesonide nasal spray to treat hyposmia associated with COVID-19
11	Anosmia rehabilitation in patients post coronavirus disease (COVID 19)	RCT, 2 arm +1 control	Not yet recruiting	Canada, single center	Budesonide with the nasal irrigations as treatment
12	Neurocognitive impairment in patients with COVID-19	Case–control prospective study Follow-up after 3 mo	Recruiting	Germany, multicenter	Using biomarkers of neuroaxonal injury and scales to assess the neurocognitive performance of study participants
13	Prospective Registry of Corona Virus Disease 2019 (COVID-19) patients with neuromuscular involvement	Prospective cohort study	Recruiting	Germany, Single center	Multimodal assessment of neuromuscular pathology associated with SARS-CoV-2 infection
14	Chronic fatigue etiology and recovery in COVID-19 patients: the role of fatigability	Nonrandomized trial	Not yet recruiting	France, multicenter	To determine whether deteriorated neuromuscular function is involved in the feeling of fatigue of COVID-19 patients

Abbreviations: ARDS, acute respiratory distress syndrome; COVID-19, novel coronavirus; CRS, cytokine release syndrome; RCT, randomized controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.